Anlotinib Capsules in the Treatment for IPF/PF-ILDs — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Anlotinib Capsules in the Treatment for IPF/PF-ILDs — Stella

Home/Interstitial Lung Diseases/

View on ClinicalTrials.gov

Recruiting

Back to Interstitial Lung Diseases trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

First Affiliated Hospital of Wenzhou Medical University

Collaborators

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Enrollment target

~30 participants

Started

September 2021

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

Age range

40 Years – 85 Years

Last updated February 2026